{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:25:05Z","timestamp":1791923105409,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472998"],"award-info":[{"award-number":["82472998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2026\\u202FM791574"],"award-info":[{"award-number":["2026\\u202FM791574"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117325","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:43:53Z","timestamp":1787802233000},"page":"117325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4891-2143","authenticated-orcid":false,"given":"Mengjia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5696-9662","authenticated-orcid":false,"given":"Guoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3338-9994","authenticated-orcid":false,"given":"Jimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-5625","authenticated-orcid":false,"given":"Kangdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2026.117325_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and Haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.intimp.2026.117325_bb0015","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.4049\/jimmunol.1700380","article-title":"T cell-derived CD70 delivers an immune checkpoint function in inflammatory T cell responses","volume":"199","author":"O\u2019Neill","year":"2017","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117325_bb0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cncr.31912","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma","volume":"125","author":"Pal","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10142-023-00977-6","article-title":"Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer","volume":"23","author":"Kong","year":"2023","journal-title":"Funct. Integr. Genomics"},{"issue":"21","key":"10.1016\/j.intimp.2026.117325_bb0035","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","article-title":"Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies","volume":"23","author":"Aftimos","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.117325_bb0040","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/bloodadvances.2021005714","article-title":"Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models","volume":"6","author":"Wu","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00280-015-2909-2","article-title":"First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70","volume":"77","author":"Owonikoko","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117325_bb0050","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.117325_bb0060","article-title":"Chimeric antigen receptor T-cell therapy in patients with lymphoma: a machine learning-driven decadal informatics network analysis","volume":"112","author":"Guo","year":"2025","journal-title":"Int. J. Surg."},{"issue":"5","key":"10.1016\/j.intimp.2026.117325_bb0065","article-title":"CD70 CAR T cells in AML: form follows function","volume":"3","author":"Mirazee","year":"2022","journal-title":"Cell Rep Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.117325_bb0070","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.hoc.2023.06.004","article-title":"Chimeric antigen receptor T cells in acute myeloid leukemia","volume":"37","author":"Cummins","year":"2023","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"22","key":"10.1016\/j.intimp.2026.117325_bb0075","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"issue":"24","key":"10.1016\/j.intimp.2026.117325_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246157","article-title":"Current limitations and perspectives of chimeric antigen receptor-T-cells in acute myeloid leukemia","volume":"13","author":"Maucher","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.intimp.2026.117325_bb0090","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117325_bb0095","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.117325_bb0100","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clgc.2016.10.008","article-title":"Impact of sequencing targeted therapies with high-dose Interleukin-2 immunotherapy: an analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational IL-2 clinical trial: PROCLAIM(SM)","volume":"15","author":"Clark","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2026.117325_bb0115","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran\u00e7ais d\u2019Immunoth\u00e9rapie","volume":"338","author":"Negrier","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.intimp.2026.117325_bb0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","article-title":"Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma","volume":"108","author":"Auvray","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.117325_bb0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41416-018-0104-z","article-title":"The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma","volume":"119","author":"Barata","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117325_bb0135","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdw160","article-title":"Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma","volume":"27","author":"Nadal","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","article-title":"Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia","volume":"10","author":"Wei","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2026.117325_bb0145","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","article-title":"Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 Axis to improve the anti-tumor efficacy of CAR-T cells on breast Cancer in mice","volume":"29","author":"Sun","year":"2021","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2026.117325_bb0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.intimp.2026.117325_bb0160","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0165","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2282250","article-title":"A novel FC-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC","volume":"12","author":"Wu","year":"2023","journal-title":"Oncoimmunology"},{"issue":"Pt 1","key":"10.1016\/j.intimp.2026.117325_bb0170","article-title":"CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCC","volume":"168","author":"Liu","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.117325_bb0175","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117325_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013024","article-title":"TNF-\u03b1 and IFN-\u03b3 differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity","volume":"13","author":"Sponheimer","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117325_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115597","article-title":"Engineering scFv immunotherapies: from CAR T cells to bispecific antibodies","volume":"166","author":"Jamali","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117325_bb0190","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","article-title":"Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2026.117325_bb0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.117325_bb0200","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jgg.2019.06.007","article-title":"Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells","volume":"46","author":"Gao","year":"2019","journal-title":"J. Genet. Genomics"},{"issue":"13","key":"10.1016\/j.intimp.2026.117325_bb0205","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.intimp.2026.117325_bb0210","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv."},{"issue":"13","key":"10.1016\/j.intimp.2026.117325_bb0215","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117325_bb0220","doi-asserted-by":"crossref","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, et al. Lymphodepletion \u2013 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front. Immunol. 2023;Volume 14\u20132023.","DOI":"10.3389\/fimmu.2023.1303935"},{"issue":"5","key":"10.1016\/j.intimp.2026.117325_bb0225","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41375-026-02930-5","article-title":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia","volume":"40","author":"Li","year":"2026","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.intimp.2026.117325_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009960","article-title":"Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells","volume":"12","author":"Qi","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117325_bb0235","article-title":"A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells","volume":"15-2024","author":"Zhang","year":"2025","journal-title":"Front. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:42:56Z","timestamp":1790437376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"alternative-id":["S1567576926011720"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117325","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humanized CD70-targeted CAR-T cells with reduced fratricide demonstrate potent antitumor activity against AML and RCC","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117325","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117325"}}